newsfilter
← Latest News
Business Wire·

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine's Psychedelic Effects on Cerebral Cortex Hemodynamics

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel's feasibility study of its Kernel Flow technology to measure Ketamine's ps